Peptide Synthesis Market Size, Top Share, Forecast To 2033

(MENAFN- Straits Research) Introduction

Peptide synthesis involves the formation of peptides by the sequential linkage of amino acids. Peptides are concise sequences of amino acids, crucial for numerous biological processes. Peptide synthesis is essential in drug discovery, diagnostics, and manufacturing vaccines, hormones, and enzymes. It is used in the pharmaceutical, biotechnology, and research sectors to advance peptide-based medicines, vaccines, and other biopharmaceuticals. Owing to their selectivity and reduced adverse effects, peptides are progressively utilized as targeted treatments, rendering peptide synthesis essential in advanced pharmaceutical research.

The demand for peptide-based medicines is a primary catalyst for the peptide synthesis market. The rising incidence of chronic diseases, including cancer, diabetes, and neurological disorders, has heightened the demand for targeted peptide treatments. Furthermore, innovations in peptide synthesis technologies, including solid-phase peptide synthesis (SPPS) and microwave-assisted peptide synthesis, have enhanced the efficiency and yield of peptide manufacturing. The growing emphasis on customized medicine and biologics within the healthcare sector is propelling the usage of peptides, hence stimulating market expansion.

Market Dynamics Increasing need for peptide therapies drives market growth

The increase in demand for peptide-based therapies is a significant factor propelling the worldwide peptide synthesis market. Peptides are progressively preferred in pharmacological development owing to their elevated specificity, lower toxicity, and effectiveness in regulating intricate biological processes. Their capacity to target protein-protein interactions and bind to receptors with high affinity renders them optimal for treating diseases such as cancer, metabolic disorders, cardiovascular problems, and autoimmune diseases.

• In July 2024, the American Cancer Society anticipated a 5% increase in peptide-based oncology treatments, underscoring their expanding significance in customized medicine. The efficacy of GLP-1 analogs in treating type 2 diabetes and obesity has intensified interest in peptide pharmaceuticals. In contrast to monoclonal antibodies, peptides present benefits like reduced production expenses, expedited development timelines, and enhanced formulation for non-invasive administration.

The increasing pipeline of peptide medications in clinical trials and the growing number of regulatory approvals indicate that the market is set for significant growth in the coming decade.

Innovative applications in vaccine formulation and diagnostic methodologies create tremendous opportunities

The increasing utilization of peptide synthesis in vaccine development and diagnostic testing offers significant potential prospects for the global industry. In recent years, peptides have become essential in developing next-generation vaccines, particularly as epitope-based vaccinations that elicit focused and safer immune responses. Companies such as CureVac and Boehringer Ingelheim are utilizing synthetic peptides to formulate mRNA vaccines, wherein peptides facilitate the synthesis of antigenic proteins.

• In April 2024, CureVac collaborated with Boehringer Ingelheim to address evolving influenza virus strains using sophisticated peptide-based technology.

With global healthcare systems emphasizing early detection and precision medicine, the need for peptide-based tools is anticipated to increase, generating significant potential for synthesis technology suppliers in both therapeutic and diagnostic fields.

Regional Analysis

Europe possesses the predominant market share in the worldwide peptide synthesis sector, attributed to its robust pharmaceutical and biotechnology industries. Germany, the United Kingdom, and France have a strong research foundation and host numerous prominent entities in peptide therapies, including Bayer and Roche. The region is renowned for its stringent and superior manufacturing standards, establishing it as a center for peptide-based medicine research. EIT Health, a European initiative, endorses biotech businesses specializing in peptide-based therapies, fostering innovation in peptide therapeutics and drug development. Europe's emphasis on regulatory compliance and environmental practices, particularly in biologics production, significantly contributes to the expansion of the peptide synthesis market.

Key Highlights

• The global peptide synthesis market size was valued at USD 667.26 million in 2024 and is projected to reach from USD 750.66 million in 2025 to USD 1926.05 million by 2033 , growing at a CAGR of 12.5% during the forecast period (2025-2033).

• By product type, the market is segmented based on reagents, peptide synthesizers, and resins. Reagents hold a dominant position.
• By application, the market is segmented based on drug development, research and diagnostics, therapeutics, vaccine development, and others. Drug Development is the largest application segment.
• By end-user, the market is segmented based on pharmaceutical and biotech companies, academic and research institutes, contract research organizations (CROs), and diagnostic laboratories. Pharmaceutical and Biotech Companies represent the leading end-user segment.
• By technology, the market is segmented based on Solid-Phase Peptide Synthesis (SPPS), Liquid-Phase Peptide Synthesis (LPPS), and Hybrid Synthesis. Solid-Phase Peptide Synthesis (SPPS) is the dominant technology.
• Based on region, the global market is segmented into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. North America dominates the global market.

Competitive Players

Merck KGaA

Thermo Fisher Scientific Inc.

GenScript

Novozymes A/S

Bachem Holding AG

MP Biomedicals

Lonza

PuroSynth

Syngene

Polypeptide Group

Creative Diagnostics

Thermo Fischer Scientific Inc.

CEM Corporation

Biotage

Kaneka Corporation

Recent Developments

• In January 2025, Bachem acquired Peptides International, expanding its portfolio of custom peptides for biotech and pharmaceutical applications, particularly focusing on oncology and immunotherapy peptides.
• In October 2024 , Thermo Fisher Scientific launched a new peptide synthesis platform that integrates high-throughput capabilities with high-quality peptide production, enabling faster drug discovery and clinical research turnaround times.

Segmentation

By Product Type

Reagents

Peptide Synthesizers

Resins

By Application

Drug Development

Research and Diagnostics

Therapeutics

Vaccine Development

Others (Cosmetics, Food, and Agriculture)

By End-User

Pharmaceutical and Biotech Companies

Academic and Research Institutes

Contract Research Organizations (CROs)

Diagnostic Laboratories

By Technology

Solid-Phase Peptide Synthesis (SPPS)

Liquid-Phase Peptide Synthesis (LPPS)

Hybrid Synthesis

By Region

North America

Europe

Asia-Pacific

Latin America

The Middle East and Africa

MENAFN08052025004597010339ID1109522814